Search
for
Sort by
Research 31–60 of 1000+
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
- Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
- A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- Erosive Pustular Dermatosis of the Scalp Due to Afatinib: A Rare Case
- Retrospective Comparison of Inflammatory Markers in Severe Acne Vulgaris Patients and Normal Population
- Hair Changes due to Drugs
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
- ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Medical Dermatology
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
- LPA-producing enzyme PA-PLA<sub>1</sub>α regulates hair follicle development by modulating EGFR signalling
- Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- KGF and EGF signalling block hair follicle induction and promote interfollicular epidermal fate in developing mouse skin
- EGFR signaling is required for regenerative proliferation in the cochlea: Conservation in birds and mammals
- Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Cutaneous side-effects of EGFR inhibitors and their management.